The FDA’s approval of Eli Lilly’s once-daily oral GLP-1 receptor agonist marks a pivotal shift in how obesity may be treated.
A pill that rewrites the rulebook
On April 1, 2026, the FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist developed by Eli Lilly for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Foundayo is a small molecule, non-peptide drug and meaningfully different molecular type from existing oral and injectable GLP-1 therapies.
Its approval also marks a regulatory milestone: Foundayo is the first new molecular entity cleared under the FDA’s new Commissioner’s National Priority Voucher (CNPV) pilot program, completing its review in just 50 days; the fastest approval of a new molecular entity since 2002, and nearly 10 months ahead of its original PDUFA date.
The science behind the swallow
Foundayo works by activating GLP-1 receptors, mimicking the hormone GLP-1 that is naturally released after eating, helping patients feel fuller for longer, slowing gastric emptying, and supporting insulin regulation. Unlike the GLP-1 agents in Lilly’s injectable lineup (Mounjaro and Zepbound), which target both GLP-1 and GIP receptors, Foundayo is a selective GLP-1 receptor agonist, making it molecularly distinct from both those products and from the peptide-based semaglutide found in Wegovy and Ozempic.
Approval was supported by data from the Phase 3 ATTAIN clinical program, which enrolled more than 4,500 adults. In a key trial, participants on the highest dose of Foundayo lost an average of 27.3 pounds over 72 weeks, compared to 2.2 pounds on placebo. At the highest dose, this represented approximately 12% total body weight loss, alongside statistically significant improvements in cardiometabolic risk factors including blood pressure and lipid levels. Notably, a separate Phase 3 trial demonstrated that patients who had previously lost weight on injectable GLP-1 agents and then switched to Foundayo experienced strong weight maintenance, with minimal average regain thus positioning it as a potential oral step-down option for patients transitioning off injectables.
Not just another GLP-1
The defining clinical differentiator for Foundayo is its unrestricted dosing window. It can be taken at any time of day, with or without food or water unlike oral semaglutide (Wegovy pill), which must be taken on an empty stomach in the morning with a limited amount of water, followed by a mandatory 30-minute wait before eating or drinking. For patients who struggle with rigid morning routines or who have found adherence to those restrictions challenging, Foundayo offers a genuine practical advantage.
In terms of efficacy, Foundayo’s average weight loss of approximately 12% compares modestly to oral semaglutide’s reported 16–17% in trials, and to injectable agents which have consistently demonstrated greater than 20% weight loss. However, no head-to-head trials have been conducted between Foundayo and other agents, and individual patient response, tolerability, and adherence often matter more in practice than trial averages.
Tearing down the treatment gap
The approval of Foundayo has the potential to bring GLP-1 therapy to a much broader population. By Lilly’s own estimates, fewer than 1 in 10 people who could benefit from a GLP-1 medication are currently taking one, held back by injection aversion, stigma, cost, and perceived complexity. An oral option that can fit seamlessly into any daily routine removes several of those barriers at once.
One important counseling point for patients on hormonal contraceptives: Lilly has noted that oral birth control pills may be less effective while taking Foundayo, and patients should be advised to discuss alternative or additional contraceptive methods with their provider.
A new tool in the clinical toolkit
For prescribers, Foundayo expands the decision tree in a meaningful way. It offers a viable starting option for patients who are reluctant to self-inject, those who have stalled on initiating therapy due to perceived complexity, and those who may benefit from a lower-cost entry point into GLP-1 treatment. Its studied role as a maintenance therapy after injectable GLP-1 use also creates a new clinical pathway: initiating weight loss with a more potent injectable, then transitioning to an oral regimen for long-term maintenance.
Additional indications are currently under investigation, including obstructive sleep apnea, hypertension, osteoarthritis knee pain, peripheral artery disease, and stress urinary incontinence, with several submissions anticipated to the FDA in the coming months and years.
The counseling conversation just got busier
Pharmacists are positioned at the front lines of this approval and should prepare for a meaningful surge in Foundayo prescriptions in the near term. High-volume patient counseling will be essential, particularly around three areas: titration expectations, side effect management, and the drug’s key distinction from other oral GLP-1 options.
Patients should be counseled to expect a gradual titration process and should be prepared for the GI side effects that are common to the class such as nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal discomfort, headache, fatigue, and hair loss are among the most frequently reported.
Pharmacists should also proactively address the question many patients will ask: how does this compare to Wegovy or Ozempic? The key talking points are the unrestricted dosing schedule, the oral format, and the appropriate expectation that weight loss may be somewhat less than what is seen with dual-agonist injectables.
The opportunity in front of us
Foundayo represents a genuine step forward in making GLP-1 therapy accessible and practical for a broader patient population. Its once-daily, unrestricted-dosing oral formulation addresses real-world barriers that have limited uptake of this drug class, and its clinical evidence supports meaningful weight loss and cardiometabolic benefit. For the pharmacy team, this approval arrives with both an opportunity and a responsibility; to counsel patients clearly, support appropriate expectations, and help ensure that those who can benefit from this therapy actually reach and stay on it.
Sources
U.S. Food and Drug Administration — FDA approves first new molecular entity under National Priority Voucher Program, April 1, 2026. fda.gov
Eli Lilly and Company — Foundayo (orforglipron) prescribing information, April 2026. foundayo.lilly.com
Eli Lilly and Company — FDA approves Lilly’s Foundayo (orforglipron) press release, April 1, 2026. prnewswire.com
Wharton S, Aronne LJ, et al. — ATTAIN-1: Orforglipron for obesity treatment, New England Journal of Medicine, November 2025. nejm.org
Horn DB, Ryan DH, et al. — ATTAIN-2: Orforglipron for obesity in people with type 2 diabetes, The Lancet, November 2025. thelancet.com
Eli Lilly and Company — ATTAIN-MAINTAIN trial topline results press release, December 18, 2025. prnewswire.com
